{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:57Z","timestamp":1777934637204,"version":"3.51.4"},"reference-count":40,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Many hospitals are now investing in robotic compounding system for the preparation of cytotoxic agents. The objective of the present study was to describe contamination by cytotoxics inside and outside the RIVA\n                      <jats:sup>TM<\/jats:sup>\n                      robot (ARxIUM, Winnipeg, Canada).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material &amp; Methods<\/jats:title>\n                    <jats:p>\n                      We applied a risk analysis to determine which locations inside and outside the compounding robot should be monitored. Samples were collected by swabbing with a wet swab (using 0.1 mL of sterile water) before the robots was cleaned. Ten cytotoxics compounded with the robot were screened for using LC-MS\/MS. We determined the percentage contamination rates inside (CR\n                      <jats:sub>in<\/jats:sub>\n                      ) and outside (CR\n                      <jats:sub>out<\/jats:sub>\n                      ) the robot and the amounts of each contaminant (in ng\/cm\u00b2). If a sample was found to be positive, a corrective action was implemented.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our risk analysis highlighted 10 locations inside the robot and 7 outside. Ten sampling campaigns (10 samples per campaign) were performed. The mean CR\n                      <jats:sub>in<\/jats:sub>\n                      (40%) was significantly higher than the mean CR\n                      <jats:sub>out<\/jats:sub>\n                      (2%; p\u2009&lt;\u200910\n                      <jats:sup>\u22124<\/jats:sup>\n                      ). Gemcitabine and cyclophosphamide were the main contaminants. After the implementation of corrective measures (such as daily cleaning with SDS\/isopropyl alcohol), the CR\n                      <jats:sub>in<\/jats:sub>\n                      fell from 60% to 10%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion\/conclusion<\/jats:title>\n                    <jats:p>The frequency of contamination was lower for robotic compounding than for manual compounding in an isolator. However, robotic compounding tended to generated larger mean amounts of contaminant; this was related to incidents such as splashing when syringes were disposed of after the compounding. The implementation of corrective actions effectively reduced the CRs. Further longer-term studies are required to confirm these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241276530","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T03:06:15Z","timestamp":1724641575000},"page":"1061-1070","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of chemical contamination by cancer drugs during use of the RIVA\n                    <sup>TM<\/sup>\n                    compounding robot: A pilot study"],"prefix":"10.1177","volume":"31","author":[{"given":"Myriam","family":"Bouchfaa","sequence":"first","affiliation":[{"name":"CHU Lille"},{"name":"Univ. Lille, ULR 7365 \u2013 GRITA \u2013 Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7580-3471","authenticated-orcid":false,"given":"Mich\u00e8le","family":"Vasseur","sequence":"additional","affiliation":[{"name":"CHU Lille"},{"name":"Univ. Lille, ULR 7365 \u2013 GRITA \u2013 Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Courtin","sequence":"additional","affiliation":[{"name":"CHU Lille"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Pinturaud","sequence":"additional","affiliation":[{"name":"CHU Lille"},{"name":"Univ. Lille, ULR 7365 \u2013 GRITA \u2013 Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Beauval","sequence":"additional","affiliation":[{"name":"Univ. Lille, ULR 4483-IMPECS-IMPact de l\u2019Environnement Chimique sur la Sant\u00e9 humaine, Lille, France"},{"name":"CHU Lille, P\u00f4le Biologie-Pathologie-G\u00e9n\u00e9tique, Unit\u00e9 Fonctionnelle de Toxicologie, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Allorge","sequence":"additional","affiliation":[{"name":"Univ. Lille, ULR 4483-IMPECS-IMPact de l\u2019Environnement Chimique sur la Sant\u00e9 humaine, Lille, France"},{"name":"CHU Lille, P\u00f4le Biologie-Pathologie-G\u00e9n\u00e9tique, Unit\u00e9 Fonctionnelle de Toxicologie, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Odou","sequence":"additional","affiliation":[{"name":"CHU Lille"},{"name":"Univ. Lille, ULR 7365 \u2013 GRITA \u2013 Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-440X","authenticated-orcid":false,"given":"Nicolas","family":"Simon","sequence":"additional","affiliation":[{"name":"CHU Lille"},{"name":"Univ. Lille, ULR 7365 \u2013 GRITA \u2013 Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000000249"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210381931"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198511073131901"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/jat.1735"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920040-00004"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijheh.2023.114264"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20064952"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e3181f72b63"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00420-007-0284-y"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210380485"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155211402106"},{"key":"e_1_3_4_13_2","unstructured":"Agence Nationale de S\u00e9curit\u00e9 des M\u00e9dicaments et des produits de sant\u00e9. Bonnes Pratiques de Pr\u00e9paration https:\/\/ansm.sante.fr\/documents\/reference\/bonnes-pratiques-de-preparation (Edition 2023 accessed 26 October 2023)."},{"key":"e_1_3_4_14_2","unstructured":"Pharmaceutical inspection convention pharmaceutical inspection co-operation scheme. PIC\/S guide to good practices for the preparation of medicinal products in healthcare establishments \u2013 PE 010-4 https:\/\/picscheme.org\/en\/publications (2014 accessed 26 October 2023)."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp180564"},{"key":"e_1_3_4_16_2","unstructured":"National Institute of Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings https:\/\/www.cdc.gov\/niosh\/docs\/2016-161\/pdfs\/2016-161.pdf (2016)."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211070933"},{"key":"e_1_3_4_18_2","unstructured":"US Pharmacopeia. USP General chapter <800> Hazardous drugs \u2013 handling in healthcare settings. www.usp.org (accessed 26 October 2023)."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213517127"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4803-204"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/annhyg\/mev031"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211072877"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2022-108623"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v65i6.1190"},{"key":"e_1_3_4_25_2","first-page":"611","article-title":"A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals","volume":"49","author":"Acampora A","year":"2005","unstructured":"Acampora A, Castiglia L, Miraglia N, et al. A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Ann Occup Hyg 2005; 49: 611\u2013618.","journal-title":"Ann Occup Hyg"},{"key":"e_1_3_4_26_2","first-page":"619","article-title":"Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators","volume":"49","author":"Crauste-Manciet S","year":"2005","unstructured":"Crauste-Manciet S, Sessink PJM, Ferrari S, et al. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg 2005; 49: 619\u2013628.","journal-title":"Ann Occup Hyg"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159052"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201335"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2012.000600"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/001857870303800213"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214551316"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1515\/pthp-2018-0018"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214522840"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231170792"},{"key":"e_1_3_4_35_2","unstructured":"Allersma D Odou P Gareb P. Equipment. In: Le Brun P Crauste-Manciet S Kr\u00e4mer I Smith J and Woerdenbag H (eds) Practical pharmaceutics. Cham: Springer."},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1515\/pthp-2018-0012"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218823911"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2012-000074.175"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4904-355"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080621"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213482683"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241276530","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241276530","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241276530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:30:13Z","timestamp":1777689013000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241276530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/10781552241276530"],"URL":"https:\/\/doi.org\/10.1177\/10781552241276530","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]}}}